Offringa R, van der Burg S H, Ossendorp F, Toes R E, Melief C J
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, The Netherlands.
Curr Opin Immunol. 2000 Oct;12(5):576-82. doi: 10.1016/s0952-7915(00)00145-x.
After studies in preclinical mouse models, the efficacy and safety of tumor-specific vaccination strategies is currently being evaluated in cancer patients. The first wave of clinical trials has shown that in general such vaccination strategies are safe. However examples of clinical responses, especially in conjunction with vaccine-induced immune responses, are still scarce. The fact that most trials have so far been performed with end-stage cancer patients can largely account for this deficit. Greater efficacy of anticancer vaccines is expected in patients with less-progressed disease. In addition, the detection of both natural and vaccine-induced T cell immunity needs further improvement.
在对临床前小鼠模型进行研究之后，目前正在癌症患者中评估肿瘤特异性疫苗接种策略的疗效和安全性。第一波临床试验表明，总体而言，此类疫苗接种策略是安全的。然而，临床反应的实例，尤其是与疫苗诱导的免疫反应相关的实例，仍然很少。到目前为止，大多数试验都是在晚期癌症患者中进行的，这在很大程度上可以解释这一不足。预计在病情进展较慢的患者中，抗癌疫苗的疗效会更高。此外，对天然和疫苗诱导的T细胞免疫的检测需要进一步改进。
